Abstract: A pharmaceutical product comprising an aqueous prostaglandin formulation and a polypropylene container are disclosed. Aqueous prostaglandin formulations are more stable in polypropylene containers than polyethylene containers.
Type:
Grant
Filed:
January 20, 2000
Date of Patent:
May 22, 2001
Assignee:
Alcon Laboratories, Inc.
Inventors:
Alan L. Weiner, Subhash C. Airy, Cody Yarborough, Julia A. Clifford, William E. McCune
Abstract: Composition and methods for treating ocular allergic reactions are disclosed. In particular, the invention is directed to compounds which inhibit human conjunctival mast cell degranulation.
Abstract: Bicomposite intraocular lenses having an anterior surface material different from a posterior surface material are disclosed. The posterior surface material reduces the risk of posterior capsule opacification.
Type:
Grant
Filed:
April 1, 1999
Date of Patent:
April 3, 2001
Assignee:
Alcon Laboratories, Inc.
Inventors:
John W. Sheets, Jr., Albert R. Leboeuf, Anilbhai S. Patel, Mutlu Karakelle, Stephen J. Van Noy
Abstract: Anionic surfactants are used in conjunction with an antifungal acid and a chelating agent to preserve topically administrable pharmaceutical compositions without the need for a conventional preservative such as benzalkonium chloride.
Type:
Grant
Filed:
September 21, 1999
Date of Patent:
April 3, 2001
Assignee:
Alcon Laboratories, Inc.
Inventors:
Ernesto J. Castillo, Steven Howard Gerson, Wesley Wehsin Han
Abstract: The present invention relates to the pharmaceutical treatment of pain. In particular, the present invention relates to the topical use of kappa opioid receptor agonists and partial agonists for the prevention or alleviation of pain in the eye.
Abstract: Intraocular lens coating compositions for reducing the risk of posterior capsule opacification are disclosed. The coating materials, which differ from the substrate material, consist essentially of at least two aryl acrylic hydrophobic monomers of the formula
wherein:
X is H or CH3;
m is 0-10;
Y is nothing, O, S, or NR wherein R is H, CH3, CnH2n+1 (n=1−10) iso OC3H7, C6H5, or CH2C6H5;
Ar is any aromatic ring which can be unsubstituted or substituted with CH3, C2H5, n-C3H7, iso-C3H7, OCH3, C6H11, Cl, Br, C6H5, or CH2C6H5.
Type:
Grant
Filed:
April 1, 1999
Date of Patent:
February 13, 2001
Assignee:
Alcon Laboratories, Inc.
Inventors:
John W. Sheets, Jr., Albert R. Leboeuf, Anilbhai S. Patel, Mutlu Karakelle, Stephen J. Van Noy
Abstract: A method of polishing articles comprising soft acrylic materials is disclosed. The method includes a polishing step and a cleaning step. In the polishing step a receptacle is charged with polishing beads of various sizes, alumina, sodium hydroxide, water, a surfactant, and the articles to be polished, and agitated for a period of time and at a speed sufficient to remove surface irregularities. The polishing step is completed below the glass transition (Tg) point of the acrylic article being polished but above 0° C. Following the polishing step, the polished articles are cleaned by rinsing them with water for a period of time to clean the surface of the polished articles.
Type:
Grant
Filed:
December 2, 1999
Date of Patent:
February 13, 2001
Assignee:
Alcon Laboratories, Inc.
Inventors:
Bryan L. Cremeans, Teresa L. Pickett, Jennia Tucker
Abstract: In vivo polymerizable intraocular lens compositions which comprise substituted fluoroalkyl or perfluoroalkyl monomers having anionic, cationic, and/or nonionic surface active functionality in the unsaturated fluorophobic ends. The compositions are preferably cured by UV photoinitiation and are useful in repairing torn or detached retinal tissue or forming intraocular lenses in situ.
Type:
Grant
Filed:
May 17, 1999
Date of Patent:
January 30, 2001
Assignees:
Alcon Laboratories, Inc., University of Southern Mississippi
Inventors:
Mark E. Hammer, Steven T. Charles, John C. Lang, Robert Y. Lochhead, Lon J. Mathias
Abstract: Ophthalmic drug delivery vehicles which are administrable as a liquid and which gel upon contact with the eyes are disclosed. The vehicles contain xanthan gum.
Type:
Grant
Filed:
March 26, 1999
Date of Patent:
January 16, 2001
Assignee:
Alcon Laboratories, Inc.
Inventors:
Rajan Bawa, Rex E. Hall, Bhagwati P. Kabra, James E. Teague
Abstract: Ophthalmic formulations containing as an active ingredient 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid or a pharmaceutically acceptable salt thereof are useful for inhibiting cytokine release (e.g., IL-6 and IL-8) from human ocular cells. Such formulations can be used to treat or prevent ocular neovascularization and non-allergic inflammatory disorders such as dry-eye, keratitis, blepharitis, uveitis and inflammation related to infection.
Type:
Grant
Filed:
June 15, 1999
Date of Patent:
January 16, 2001
Assignee:
Alcon Laboratories, Inc.
Inventors:
John M. Yanni, Daniel A. Gamache, Lori K. Weimer
Abstract: Compositions and methods for treating otic pain are disclosed. In particular, the invention discloses compositions and methods of using kappa opioid agonists locally for the prevention or alleviation of otic pain.
Abstract: Simple, efficacious, easily manufacturable, convenient to use and cost-effective contact lens care cleaning compositions comprising carbon dioxide and carbonic acid as cleansing agents are disclosed. The compositions do not require abrasive agents such as polymeric beads, nor ocularly irritating agents such as enzymes or surfactants in order to effectively clean proteinaceous and nonproteinaceous deposits from the surface of contact lenses. Also disclosed is a one-step cleaning and disinfecting regimen, whereby an effervescent tablet composition capable of generating carbon dioxide and carbonic acid is dissolved in a disinfecting solution or rinsing/disinfecting/storage solution.
Type:
Grant
Filed:
April 22, 1999
Date of Patent:
January 9, 2001
Assignee:
Alcon Laboratories, Inc.
Inventors:
Rajkumar Bhatia, Alok K. Kulshreshtha, Geoffrey R. Owen, Yusuf Ali
Abstract: Anionic amino acid based surfactants are used to enhance antimicrobial effectiveness in topically administrable pharmaceutical compositions containing at least one active ingredient, a cationic preservative and an anionic polyelectrolyte, such as carboxyvinyl polymers, xanthan gum, polystyrene sulfonic acid polymers and cationic exchange resins.
Type:
Grant
Filed:
September 21, 1999
Date of Patent:
November 14, 2000
Assignee:
Alcon Laboratories, Inc.
Inventors:
Ernesto J. Castillo, Steven Howard Gerson, Wesley Wehsin Han
Abstract: Coatings for surgical instruments which comprise substituted fluoroalkyl or perfluoroalkyl monomers having anionic, cationic, and/or nonionic surface active functionality in the unsaturated fluorophobic ends.
Type:
Grant
Filed:
January 23, 1998
Date of Patent:
September 26, 2000
Assignees:
Alcon Laboratories, Inc., University of Southern Mississippi
Inventors:
Mark E. Hammer, Steven T. Charles, John C. Lang, Robert Y. Lochhead, Lon J. Mathias
Abstract: A method for polishing articles comprising soft acrylic materials is disclosed. The method includes a polishing step and a cleaning step. In the polishing step, a receptacle is charged with polishing beads of various sizes, alumina, a swelling agent and the articles to be polished, and agitated for a period of time and at a speed sufficient to remove surface irregularities. Following the polishing step, the polished articles are cleaned by agitating them with a cleaning slurry comprising cleaning beads of various sizes, alumina, a solvent and a surfactant for a period of time and at a speed sufficient to clean the surface of the polished articles. Agitation is preferably accomplished by a tumbling machine.
Abstract: 16.alpha., 17.alpha.-dialkylated steroids are prepared by reacting a 16.alpha.-alkyl-17(20)-enyl-20-silyl ether with an alkylating agent and an enol silyl ether cleaving agent in a suitable solvent.
Abstract: An improved model of endotoxin-induced inflammation is obtained by eliminating the interference in the biochemical assay of myeloperoxidase caused by endogenous reductants and cellular constituents containing free thiol functional groups. The interference was eliminated by 1) extensively diluting soluble, interfering substances and 2) blocking tissue sulfhydril functional groups during tissue homogenization. The improved model can be used to assess the therapeutic potential of anti-inflammatory agents. For example, the model can be used to evaluate topically administrable ophthalmic anti-inflammatory agents in Lewis rats.